Illumina(ILMN) Prnewswire·2025-03-10 20:10Core Viewpoint - Illumina is adapting to regulatory changes in China while maintaining its growth strategy and financial outlook, projecting a non-GAAP diluted EPS of approximately 4.50 for fiscal year 2025 [3]. - An incremental cost reduction program of approximately $100 million is being instituted to mitigate potential revenue impacts from the Greater China business [3][4]. Strategic Focus - Illumina aims for high-single-digit revenue growth by 2027 while expanding margins [2]. - The company is expanding its multiomics portfolio with new technologies in genomics, spatial, single cell, and methylation, alongside a new multimodal data analysis platform [2]. - Continued investment in services, data, and software offerings is planned to support core sequencing and multiomics businesses [2]. Regulatory Environment - Illumina respects the decision from the China Ministry of Commerce not to permit the export of sequencing instruments into China and will comply with all applicable laws [1]. - The company acknowledges limited further earnings contribution from China in its fiscal 2025 guidance [4]. Market Position - Illumina is recognized as a global leader in DNA sequencing and array-based technologies, serving various markets including life sciences, oncology, and agriculture [8].